JP2015525099A5 - - Google Patents

Download PDF

Info

Publication number
JP2015525099A5
JP2015525099A5 JP2015516668A JP2015516668A JP2015525099A5 JP 2015525099 A5 JP2015525099 A5 JP 2015525099A5 JP 2015516668 A JP2015516668 A JP 2015516668A JP 2015516668 A JP2015516668 A JP 2015516668A JP 2015525099 A5 JP2015525099 A5 JP 2015525099A5
Authority
JP
Japan
Prior art keywords
composition according
composition
sucrose octasulfate
hyaluronic acid
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015516668A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015525099A (ja
JP6178414B2 (ja
Filing date
Publication date
Priority claimed from FR1255543A external-priority patent/FR2991876B1/fr
Application filed filed Critical
Publication of JP2015525099A publication Critical patent/JP2015525099A/ja
Publication of JP2015525099A5 publication Critical patent/JP2015525099A5/ja
Application granted granted Critical
Publication of JP6178414B2 publication Critical patent/JP6178414B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015516668A 2012-06-13 2013-06-13 少なくとも1種のヒアルロン酸及び少なくとも1種のショ糖オクタ硫酸水溶性塩を含有する水性媒体組成物 Active JP6178414B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261659140P 2012-06-13 2012-06-13
FR1255543 2012-06-13
FR1255543A FR2991876B1 (fr) 2012-06-13 2012-06-13 Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
US61/659,140 2012-06-13
PCT/FR2013/051380 WO2013186493A2 (fr) 2012-06-13 2013-06-13 Composition, en milieux aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate

Publications (3)

Publication Number Publication Date
JP2015525099A JP2015525099A (ja) 2015-09-03
JP2015525099A5 true JP2015525099A5 (enExample) 2016-05-12
JP6178414B2 JP6178414B2 (ja) 2017-08-09

Family

ID=46785648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015516668A Active JP6178414B2 (ja) 2012-06-13 2013-06-13 少なくとも1種のヒアルロン酸及び少なくとも1種のショ糖オクタ硫酸水溶性塩を含有する水性媒体組成物

Country Status (17)

Country Link
US (1) US9314530B2 (enExample)
EP (1) EP2861301B1 (enExample)
JP (1) JP6178414B2 (enExample)
KR (1) KR20150023468A (enExample)
CN (1) CN104394934B (enExample)
AU (1) AU2013276343B2 (enExample)
BR (1) BR112014029510A2 (enExample)
CA (1) CA2876057A1 (enExample)
EA (1) EA201492208A1 (enExample)
ES (1) ES2728686T3 (enExample)
FR (1) FR2991876B1 (enExample)
IL (1) IL235776A0 (enExample)
MX (1) MX354544B (enExample)
PL (1) PL2861301T3 (enExample)
SG (1) SG11201407857SA (enExample)
TR (1) TR201907427T4 (enExample)
WO (1) WO2013186493A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3613423T (pt) 2013-07-10 2022-12-07 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e suas utilizações
US9421198B2 (en) 2013-07-30 2016-08-23 Teoxane Composition comprising hyaluronic acid and mepivacaine
FR3015290B1 (fr) * 2013-12-23 2017-01-13 Lab Vivacy Compositions d'acide hyaluronique compreant de la mepivacaine
CN106659663A (zh) * 2014-06-30 2017-05-10 纽璀克斯技术公司 控制影响角化细胞和/或成纤维细胞和真皮的皮肤失调和皮肤老化的组合产品和美容组合物
FR3032617B1 (fr) * 2015-02-16 2018-03-16 Kylane Laboratoires Sa Procede de preparation d un hydrogel injectable; hydrogel obtenu; utilisation de l hydrogel obtenu
US10004824B2 (en) 2015-05-11 2018-06-26 Laboratoires Vivacy Compositions comprising at least one polyol and at least one anesthetic
FR3036035B1 (fr) 2015-05-11 2018-10-05 Laboratoires Vivacy Compositions comprenant au moins un polyol et au moins un anesthesique
CN104926889A (zh) * 2015-05-24 2015-09-23 广西师范学院 蔗糖硫酸酯铜银类化合物及其制作方法和用途
PT3352766T (pt) * 2015-09-24 2022-03-22 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e processos para o seu uso
FR3044557B1 (fr) * 2015-12-07 2017-12-01 Benedicte Vincente Gavard Molliard Tauzin Nouvelle composition injectable; procede de preparation de ladite composition; utilisation de ladite composition
WO2017102001A1 (fr) 2015-12-16 2017-06-22 Vplus International Sa Composition d'acide hyaluronique pour injections peniennes
FR3047666A1 (fr) * 2016-02-15 2017-08-18 Benedicte Vincente Gavard Molliard Tauzin Composition injectable; procede de preparation de ladite composition; utilisation de ladite composition
FR3058064B1 (fr) 2016-10-28 2020-08-07 Lab Vivacy Composition a base d'acide hyaluronique comprenant de la mepivacaine
US20200093852A1 (en) * 2016-12-13 2020-03-26 Keats NELMS Methods of Treating Ocular Disorders
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
MX2019006863A (es) 2016-12-13 2019-09-13 Beta Therapeutics Pty Ltd Inhibidores de heparanasa y uso de los mismos.
FR3109153B1 (fr) 2020-04-10 2022-07-15 Teoxane SA Compositions à base d’au moins deux glycosaminoglycanes
KR102664134B1 (ko) * 2023-11-23 2024-05-10 한국콜마주식회사 히알루론산 및 이의 유도체를 포함하는 화장료 조성물

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2715091A (en) 1949-11-28 1955-08-09 Nat Res Dev Dextran sulfate as anticoagulant, process of preparing same, and sterile solution thereof
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
DK505488D0 (da) * 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
US5916880A (en) 1987-12-21 1999-06-29 Bukh Meditec A/S Reduction of skin wrinkling using sulphated sugars
DK86492D0 (da) 1992-06-30 1992-06-30 Bukh Meditec Laegemiddel
AU4941297A (en) 1996-11-15 1998-06-10 Dumex-Alpharma A/S A method for promoting tissue repair
JP2000178196A (ja) * 1998-12-11 2000-06-27 Seikagaku Kogyo Co Ltd 新規ヒアルロニダーゼ阻害剤及び外用剤
GB9902412D0 (en) 1999-02-03 1999-03-24 Fermentech Med Ltd Process
EP1423081A4 (en) * 2001-06-25 2005-05-25 Depuy Int Ltd COMPOSITION WITH GLYCOSAMINOGYCANES AND HYALURONIDASE INHIBITORS FOR THE TREATMENT OF ARTHRITIC JOINTS
US20050187150A1 (en) * 2001-10-31 2005-08-25 New York University Structure-based design and synthesis of FGF inhibitors and FGF modulator compounds
MXPA01011542A (es) 2001-11-13 2003-05-22 Alcon Inc Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel.
AUPS052802A0 (en) 2002-02-15 2002-03-07 Praxis Pharmaceuticals International Pty Ltd Carbohydrate-based anti-wrinkle and tissue remodelling compounds
US20080003258A1 (en) 2002-10-16 2008-01-03 Marcum Frank D Composition and Method for Treating Rheumatoid Arthritis
PT1560588E (pt) 2002-10-16 2012-01-06 Arthrodynamic Technologies Animal Health Division Inc Tratamento para sinovite traumática e lesões na cartilagem
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
GB0329907D0 (en) 2003-12-23 2004-01-28 Innomed Ltd Compositions
FR2865737B1 (fr) 2004-02-03 2006-03-31 Anteis Sa Gel reticule biocompatible
WO2006017752A2 (en) 2004-08-05 2006-02-16 Ivax Corporation Sulfated oligosaccharides
AU2005272578A1 (en) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions and methods using hyaluronic acid and hyluronidase inhibitors
WO2008011836A2 (es) 2006-07-25 2008-01-31 Osmotica Corp. Soluciones oftálmicas
JPWO2008020495A1 (ja) * 2006-08-15 2010-01-07 東京化成工業株式会社 新規阻害剤
FR2918276B1 (fr) 2007-07-02 2010-01-22 Anteis Sa "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"
ITMI20072237A1 (it) 2007-11-27 2009-05-28 Sigea Srl Esteri misti butirrico-formico di polisaccaridi acidi, loro preparazione ed uso come dermocosmetici
US8394784B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
FR2924615B1 (fr) 2007-12-07 2010-01-22 Vivacy Lab Hydrogel cohesif biodegradable.
FR2953522B1 (fr) 2009-12-07 2012-03-09 Fabre Pierre Dermo Cosmetique Sucrose octasulfates de zinc, leur preparation et leurs applications pharmaceutiques et cosmetiques
US20110171310A1 (en) 2010-01-13 2011-07-14 Allergan Industrie, Sas Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use
FR2956322A1 (fr) 2010-02-17 2011-08-19 Urgo Lab Utilisation d'oligosaccharides polysulfates synthetiques comme agents de detersion d'une plaie.
CA2805008C (en) * 2010-07-12 2015-05-12 Shin Poong Pharmaceutical Co., Ltd. Filler composition for tissue augmentation comprising a hydrogel of hyaluronic acid cross-linked with alkylene diamine
FR2983483B1 (fr) 2011-12-02 2014-11-14 Vivacy Lab Procede de substitution et reticulation simultanees d'un polysaccharide via ses fonctions hydroxyles

Similar Documents

Publication Publication Date Title
JP7362582B2 (ja) 眼科用水性組成物
Abdelkader et al. Novel in situ gelling ocular films for the opioid growth factor-receptor antagonist-naltrexone hydrochloride: Fabrication, mechanical properties, mucoadhesion, tolerability and stability studies
ES2905049T3 (es) Composición esterilizada que comprende al menos un ácido hialurónico y un fosfato de ascorbilo magnésico
JP6446462B2 (ja) メピバカインを含有するヒアルロン酸組成物
JP4694773B2 (ja) 粘膜適用液状組成物
US20160081906A1 (en) Water-soluble hyaluronic acid gel and method for producing same
JP5715400B2 (ja) ロキソプロフェン含有医薬組成物
WO2014061332A1 (ja) ヒアルロン酸ゲル及びその製造方法
JP2010511454A5 (ja) 皮内注射用ヒアルロン酸ゲル移植片
CN103520066B (zh) 一种可食性天然蜂胶抑菌牙膏及其制备方法
RU2012145616A (ru) Усовершенствованные способы и композиции для безопасного и эффективного лечения эритемы
EP2792252A3 (en) Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
NO20100301L (no) Forbedrete brimonidinsammensetninger for behandling av erytem
PT2116243E (pt) Composição de gel para tratamento de micoses
BR112012003283A8 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
AR084865A1 (es) Preparacion de desintegracion rapida, comprimido dispersable por via oral
RU2014146519A (ru) Хондроитин для применения в медицине
Kwon et al. Preparation of erythromycin-loaded poly (vinylalcohol) film and investigation of its feasibility as a transdermal delivery carrier
JP5518608B2 (ja) 粘膜適用液状組成物
JP2013173780A5 (enExample)
CN107638304B (zh) 一种高皮肤细胞渗透的α-熊果苷组合物及其制备方法和应用
ES2760523T3 (es) Composición oftálmica remanente, especialmente para el tratamiento de la sequedad ocular
ES3045060T3 (en) Topical pharmaceutical composition in the form of aqueous gel containing at least amitriptyline
JP2012036167A (ja) 内服液剤
KR102540969B1 (ko) 소듐 2-메르캅토에탄 설포네이트를 함유하는 피부 재생 촉진용 조성물